Dongting Zhangsun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/867629/publications.pdf

Version: 2024-02-01

394421 434195 54 1,058 19 31 citations h-index g-index papers 58 58 58 679 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cloning, synthesis, and characterization of $\hat{l}\pm O$ -conotoxin GeXIVA, a potent $\hat{l}\pm 9\hat{l}\pm 10$ nicotinic acetylcholine receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4026-35.	7.1	91
2	A novel α4/7â€conotoxin LvIA from Conus lividus that selectively blocks α3β2 vs. α6/α3β2β3 nicotinic acetylcholine receptors. FASEB Journal, 2014, 28, 1842-1853.	0.5	64
3	Characterization of a Novel $\hat{l}\pm$ -Conotoxin TxID from <i>Conus textile</i> Pi> That Potently Blocks Rat $\hat{l}\pm3\hat{l}^24$ Nicotinic Acetylcholine Receptors. Journal of Medicinal Chemistry, 2013, 56, 9655-9663.	6.4	63
4	Improved Agrobacterium-mediated genetic transformation of GNA transgenic sugarcane. Biologia (Poland), 2007, 62, 386-393.	1.5	53
5	Characterization of a Novel $\hat{l}\pm$ -Conotoxin from Conus textile That Selectively Targets $\hat{l}\pm6/\hat{l}\pm3\hat{l}^22\hat{l}^23$ Nicotinic Acetylcholine Receptors. Journal of Biological Chemistry, 2013, 288, 894-902.	3.4	53
6	Atypical \hat{l}_{\pm} -Conotoxin LtlA from Conus litteratus Targets a Novel Microsite of the $\hat{l}_{\pm}3\hat{l}^2$ 2 Nicotinic Receptor. Journal of Biological Chemistry, 2010, 285, 12355-12366.	3.4	49
7	A Novel Inhibitor of $\hat{l}\pm9\hat{l}\pm10$ Nicotinic Acetylcholine Receptors from Conus vexillum Delineates a New Conotoxin Superfamily. PLoS ONE, 2013, 8, e54648.	2.5	47
8	From crystal structure of \hat{l} ±-conotoxin GIC in complex with Ac-AChBP to molecular determinants of its high selectivity for \hat{l} ±3 \hat{l} 2 nAChR. Scientific Reports, 2016, 6, 22349.	3.3	41
9	The $\hat{l}\pm 9\hat{l}\pm 10$ Nicotinic Acetylcholine Receptor Antagonist $\hat{l}\pm 0$ -Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain. Marine Drugs, 2019, 17, 265.	4.6	39
10	Anti-hypersensitive effect of intramuscular administration of $\hat{l}\pm O$ -conotoxin GeXIVA[1,2] and GeXIVA[1,4] in rats of neuropathic pain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 66, 112-119.	4.8	33
11	\hat{l} ±-Conotoxin [S9A]TxID Potently Discriminates between \hat{l} ±3 \hat{l} 24 and \hat{l} ±6 \hat{l} ±3 \hat{l} 24 Nicotinic Acetylcholine Receptors. Journal of Medicinal Chemistry, 2017, 60, 5826-5833.	6.4	30
12	$\hat{l}\pm O$ -Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human $\hat{l}\pm 9\hat{l}\pm 10$ subtype. Neuropharmacology, 2017, 127, 243-252.	4.1	29
13	Discovery Methodology of Novel Conotoxins from Conus Species. Marine Drugs, 2018, 16, 417.	4.6	27
14	Novel O-superfamily Conotoxins Identified by cDNA Cloning From Three Vermivorous Conus Species. Chemical Biology and Drug Design, 2006, 68, 256-265.	3.2	26
15	Influence of Disulfide Connectivity on Structure and Bioactivity of \hat{l} ±-Conotoxin TxIA. Molecules, 2014, 19, 966-979.	3.8	23
16	Recombinant Expression and Characterization of \hat{l}_{\pm} -Conotoxin LvIA in Escherichia coli. Marine Drugs, 2016, 14, 11.	4.6	23
17	d-Amino Acid Substitution of \hat{l}_{\pm} -Conotoxin RgIA Identifies its Critical Residues and Improves the Enzymatic Stability. Marine Drugs, 2019, 17, 142.	4.6	20
18	αO-Conotoxin GeXIVA Inhibits the Growth of Breast Cancer Cells via Interaction with α9 Nicotine Acetylcholine Receptors. Marine Drugs, 2020, 18, 195.	4.6	20

#	Article	IF	CITATIONS
19	Optimal Cleavage and Oxidative Folding of $\hat{I}\pm$ -Conotoxin TxIB as a Therapeutic Candidate Peptide. Marine Drugs, 2013, 11, 3537-3553.	4.6	19
20	Alanine-Scanning Mutagenesis of α-Conotoxin GI Reveals the Residues Crucial for Activity at the Muscle Acetylcholine Receptor. Marine Drugs, 2018, 16, 507.	4.6	19
21	Single Amino Acid Substitution in Î \pm -Conotoxin TxID Reveals a Specific Î \pm 3Î 2 4 Nicotinic Acetylcholine Receptor Antagonist. Journal of Medicinal Chemistry, 2018, 61, 9256-9265.	6.4	19
22	Key Residues in the Nicotinic Acetylcholine Receptor \hat{l}^2 2 Subunit Contribute to \hat{l} ±-Conotoxin LvIA Binding. Journal of Biological Chemistry, 2015, 290, 9855-9862.	3.4	18
23	High Selectivity of an \hat{l} ±-Conotoxin LvIA Analogue for \hat{l} ±3 \hat{l} 2 Nicotinic Acetylcholine Receptors Is Mediated by \hat{l} 2 Functionally Important Residues. Journal of Medicinal Chemistry, 2020, 63, 13656-13668.	6.4	18
24	Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of αO-Conotoxin GeXIVA. Marine Drugs, 2020, 18, 61.	4.6	18
25	Species specificity of rat and human $\hat{l}\pm7$ nicotinic acetylcholine receptors towards different classes of peptide and protein antagonists. Neuropharmacology, 2018, 139, 226-237.	4.1	15
26	\hat{l}_{\pm} -Conotoxin TxIB: A Uniquely Selective Ligand for $\hat{l}_{\pm}6/\hat{l}_{\pm}3\hat{l}^22\hat{l}^23$ Nicotinic Acetylcholine Receptor Attenuates Nicotine-Induced Conditioned Place Preference in Mice. Marine Drugs, 2019, 17, 490.	4.6	14
27	Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets. Marine Drugs, 2019, 17, 256.	4.6	14
28	Effects of Cyclization on Activity and Stability of α-Conotoxin TxIB. Marine Drugs, 2020, 18, 180.	4.6	14
29	Expression, renaturation and biological activity of recombinant conotoxin GeXIVAWT. Applied Microbiology and Biotechnology, 2013, 97, 1223-1230.	3.6	13
30	Expression and secretion of functional recombinant \hat{l} 4O-conotoxin MrVIB-His-tag in Escherichia coli. Toxicon, 2013, 72, 81-89.	1.6	13
31	Expression in <i>Escherichia coli</i> of fusion protein comprising αâ€conotoxin Tx <scp>IB</scp> and preservation of selectivity to nicotinic acetylcholine receptors in the purified product. Chemical Biology and Drug Design, 2018, 91, 349-358.	3.2	13
32	Structure and Activity Studies of Disulfide-Deficient Analogues of αO-Conotoxin GeXIVA. Journal of Medicinal Chemistry, 2020, 63, 1564-1575.	6.4	13
33	Diversity of Conopeptides and Their Precursor Genes of Conus Litteratus. Marine Drugs, 2020, 18, 464.	4.6	11
34	Application of per-Residue Energy Decomposition to Design Peptide Inhibitors of PSD95 GK Domain. Frontiers in Molecular Biosciences, 2022, 9, 848353.	3.5	9
35	Effects of serum, enzyme, thiol, and forced degradation on the stabilities of αO onotoxin GeXIVA[1,2] and GeXIVA [1,4]. Chemical Biology and Drug Design, 2018, 91, 1030-1041.	3.2	8
36	DSPE-PEG Modification of α-Conotoxin TxID. Marine Drugs, 2019, 17, 342.	4.6	8

#	Article	IF	Citations
37	Novel \hat{l}_{\pm} -conotoxins identified by gene sequencing from cone snails native to Hainan, and their sequence diversity. Journal of Peptide Science, 2006, 12, 693-704.	1.4	7
38	Effect of Methionine Oxidation and Substitution of \hat{l} ±-Conotoxin TxID on \hat{l} ±3 \hat{l} ² 4 Nicotinic Acetylcholine Receptor. Marine Drugs, 2018, 16, 215.	4.6	7
39	Identification of Crucial Residues in α-Conotoxin El Inhibiting Muscle Nicotinic Acetylcholine Receptor. Toxins, 2019, 11, 603.	3.4	7
40	Engineered Conotoxin Differentially Blocks and Discriminates Rat and Human $\hat{l}\pm7$ Nicotinic Acetylcholine Receptors. Journal of Medicinal Chemistry, 2021, 64, 5620-5631.	6.4	7
41	Efficient Expression of Acetylcholine-Binding Protein from <i>Aplysia californica</i> in Bac-to-Bac System. BioMed Research International, 2014, 2014, 1-9.	1.9	6
42	Inflammation Regulation via an Agonist and Antagonists of $\hat{l}\pm7$ Nicotinic Acetylcholine Receptors in RAW264.7 Macrophages. Marine Drugs, 2022, 20, 200.	4.6	6
43	Design, Synthesis, and Activity of an α-Conotoxin LtIA Fluorescent Analogue. ACS Chemical Neuroscience, 2021, 12, 3662-3671.	3.5	5
44	\hat{l}_{\pm} -Conotoxin TxID and [S9K]TxID, $\hat{l}_{\pm}3\hat{l}^24$ nAChR Antagonists, Attenuate Expression and Reinstatement of Nicotine-Induced Conditioned Place Preference in Mice. Marine Drugs, 2020, 18, 646.	4.6	4
45	Characterization of an $\hat{l}\pm 4/7$ -Conotoxin LvIF from Conus lividus That Selectively Blocks $\hat{l}\pm 3\hat{l}^2$ 2 Nicotinic Acetylcholine Receptor. Marine Drugs, 2021, 19, 398.	4.6	4
46	Degradation kinetics of αâ€conotoxin TxID. FEBS Open Bio, 2019, 9, 1561-1572.	2.3	3
47	Cysteine [2,4] Disulfide Bond as a New Modifiable Site of α-Conotoxin TxlB. Marine Drugs, 2021, 19, 119.	4.6	3
48	α-Conotoxin TxlB Improved Behavioral Abnormality and Changed Gene Expression in Zebrafish (Danio) Tj ETQq0 0	g.ggBT /O	verlock 101
49	Oligo-basic amino acids, potential nicotinic acetylcholine receptor inhibitors. Biomedicine and Pharmacotherapy, 2022, 152, 113215.	5.6	3
50	Synthesis and evaluation of disulfide-rich cyclic \hat{l} ±-conotoxin [S9A]TxID analogues as novel \hat{l} ±3 \hat{l} ² 4 nAChR antagonists. Bioorganic Chemistry, 2021, 112, 104875.	4.1	2
51	α-Conotoxin TxlB Inhibits Development of Morphine-Induced Conditioned Place Preference in Mice via Blocking α6β2* Nicotinic Acetylcholine Receptors. Frontiers in Pharmacology, 2021, 12, 772990.	3.5	2
52	A Novel $\hat{l}\pm4/7$ -Conotoxin QulA Selectively Inhibits $\hat{l}\pm3\hat{l}^22$ and $\hat{l}\pm6/\hat{l}\pm3\hat{l}^24$ Nicotinic Acetylcholine Receptor Subtypes with High Efficacy. Marine Drugs, 2022, 20, 146.	4.6	2
53	Conotoxins and Drug Discovery With Special Reference to Hainan Species. Toxinology, 2017, , 149-187.	0.2	O
54	Conotoxins and Drug Discovery With Special Reference to Hainan Species. , 2015, , 1-39.		0